Abbvie Inc. · NYSE:ABBV
Abbvie — Jefferies Healthcare Conference 2018
11 slides from Abbvie's conference presentation, Jun 6, 2018
Slide 1: Jefferies Healthcare Conference
Jefferies Healthcare Conference June 6, 2018
Slide 2: Forward-Looking Statements and Non-GAAP Financial Information
Forward-Looking Statements and Non-GAAP Financial Information Some statements in this presentation may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions, among others, gen
Slide 3: AbbVie Immunology To Evolve From a Single Product to a Portfolio of Therapies
AbbVie Immunology To Evolve From a Single Product to a Portfolio of Therapies Differentiated Late-Stage Assets and Promising Early-Stage Programs Re-defining Standard of Care Across Immune-Mediated Diseases Rheumatology Dermatology Gastroenterology Other RA PsA AxSpA GCA PsO AD HS CD UC Market
Slide 4: SELECT Phase 3 Program for Upadacitinib in Rheumatoid Arthritis
SELECT Phase 3 Program for Upadacitinib in Rheumatoid Arthritis One of the most robust Phase 3 programs for RA ‒ 6 studies, nearly 5,000 patients, multiple patient types, 2 biologic comparators Patient csDMARD-IR MTX-naïve MTX-IR MTX-IR Biologic-IR Biologic-IR Population Scheme Combo Mono Combo Mono
Slide 5: Upadacitinib Demonstrates Compelling Data in RA
Upadacitinib Demonstrates Compelling Data in RA SELECT-EARLY results support the potential of upadacitinib as a first-line monotherapy SELECT-EARLY (week 12) • Methotrexate (MTX) is commonly used as a first-line therapy in 80% rheumatoid arthritis, but many patients do not respond to or cannot 70% t
Slide 6: Upadacitinib Demonstrates Compelling Data in RA
Upadacitinib Demonstrates Compelling Data in RA Potential to be a best-in-class therapy SELECT-NEXT (week 12) • Both doses of upadacitinib met all primary and key secondary endpoints 80% in SELECT-NEXT study. 70% 60% • Achieved very high ACR20 responses, but more importantly, upadacitinib 50% drove
Slide 7: Upadacitinib Demonstrates Compelling Data in RA
Upadacitinib Demonstrates Compelling Data in RA Potential to be a best-in-class therapy SELECT-MONOTHERAPY (week 14) • SELECT-MONOTHERAPY addressed the clinical impact of switching from 80% methotrexate to upadacitinib as monotherapy in patients with an 70% inadequate response to methotrexate. 60% 5
Slide 8: Overall Safety for Upadacitinib in the SELECT Clinical Program for Rheumatoid Arthritis
Overall Safety for Upadacitinib in the SELECT Clinical Program for Rheumatoid Arthritis Overall safety profile is consistent with mechanism of action and immunomodulatory therapies Majority of all adverse events are mild to moderate and do not result in discontinuation of therapy The most frequent s
Slide 9: Venous Thromboembolism (VTE) Data in Upadacitinib SELECT Clinical Program for Rheumatoid Arthritis
Venous Thromboembolism (VTE) Data in Upadacitinib SELECT Clinical Program for Rheumatoid Arthritis Exposure-Adjusted Incidence Rate of VTE in Upadacitinib SELECT Program (SELECT-NEXT, SELECT-BEYOND, SELECT-MONOTHERAPY, SELECT-COMPARE and SELECT-EARLY) Number of Patients with Events per 100 Patient Y
Slide 10: Upadacitinib Has Produced Strong Mid- and Late-Stage Data in Rheumatology, Dermatology and Gastroenterology
Upadacitinib Has Produced Strong Mid- and Late-Stage Data in Rheumatology, Dermatology and Gastroenterology 2018 2019 Strong results from five studies in SELECT Phase 3 program in rheumatoid arthritis support our Rheumatoid File view that upadacitinib represents potential best- Arthritis in-class th
Slide 11: Qobvie
Qobvie